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SUMMARY  
Esophageal adenocarcinoma (EAC) is thought to develop from asymptomatic Barrett’s esophagus 
(BE) with a low annual rate of conversion. Current endoscopy surveillance for BE patients is 
probably not cost-effective. Previously, we discovered serum glycoprotein biomarker candidates 
which could discriminate BE patients from EAC. Here, we aimed to validate candidate serum 
glycoprotein biomarkers in independent cohorts, and to develop a biomarker candidate panel for 
BE surveillance. Serum glycoprotein biomarker candidates were measured in 301 serum samples 
collected from Australia (4 states) and USA (1 clinic) using previously established lectin magnetic 
bead array (LeMBA) coupled multiple reaction monitoring mass spectrometry (MRM-MS) tier 3 
assay. The area under receiver operating characteristic curve (AUROC) was calculated as a 
measure of discrimination, and multivariate recursive partitioning was used to formulate a multi-
marker panel for BE surveillance. Complement C9 (C9), gelsolin (GSN), serum 
paraoxonase/arylesterase 1 (PON1) and serum paraoxonase/lactonase 3 (PON3) were validated as 
diagnostic glycoprotein biomarkers in lectin pull-down samples for EAC across both cohorts. A 
panel of 10 serum glycoprotein biomarker candidates discriminated BE patients not requiring 
intervention [BE+/- low grade dysplasia] from those requiring intervention [BE with high grade 
dysplasia (BE-HGD) or EAC] with an AUROC value of 0.93. Tissue expression of C9 was found 
to be induced in BE, dysplastic BE and EAC. In longitudinal samples from subjects that have 
progressed towards EAC, levels of serum C9 were significantly (P<0.05) increased with disease 
progression in EPHA (erythroagglutinin from Phaseolus vulgaris) and NPL (Narcissus 
pseudonarcissus lectin) pull-down samples. The results confirm alteration of complement pathway 
glycoproteins during BE-EAC pathogenesis. Further prospective clinical validation of the 
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confirmed biomarker candidates in a large cohort is warranted, prior to development of a first-line 
BE surveillance blood test.  
KEYWORDS: esophageal adenocarcinoma; Barrett’s esophagus; serum glycoprotein biomarker; 
complement pathway; multiple reaction monitoring; lectin   
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INTRODUCTION 
Esophageal cancer is the sixth most common cause of cancer related mortality in men, with 
3-fold higher rates in men than women (1, 2). Of the two main histological subtypes 
(adenocarcinoma and squamous cell carcinoma), the incidence of esophageal adenocarcinoma 
(EAC) has been rising continuously in Western countries, and accounts for the majority of cases 
(3-5). Despite aggressive treatment, EAC has a 5-year survival of less than 20% (6). EAC is 
thought to develop from the metaplastic condition Barrett’s esophagus (BE) as a consequence of 
gastroesophageal reflux disease (GERD) through a metaplasia–dysplasia–adenocarcinoma 
sequence (Figure 1A) (7-9).  
Currently, BE patients usually undergo endoscopy-biopsy surveillance with the degree of 
dysplasia assessed by histopathology as a biomarker to monitor risk of neoplastic progression (10). 
Patients diagnosed with high-grade dysplasia (BE-HGD) are treated with endoscopic mucosal 
resection, radiofrequency ablation or surgery, in an attempt to halt further disease progression (10-
12). The significant cost of endoscopy plus the low annual progression rate to HGD or EAC means 
that the cost-effectiveness of endoscopic surveillance is questioned at the population level (13-16). 
Furthermore the evaluation of dysplasia in tissue biopsies by histopathology is prone to inter-
observer variability and sampling error (17). A less costly and minimally invasive diagnostic 
procedure is needed for cost-effective screening and surveillance of at-risk populations (18, 19). 
We envisage that a blood test which can reliably discriminate BE-HGD and EAC from BE, GERD 
and healthy patients could be used to pre-select the patients for endoscopic examination, while 
reducing unnecessary endoscopy for the majority of patients in a surveillance program.  
As the first step to developing blood-based EAC diagnostic test, we focused on differential 
lectin binding of serum glycoproteins during EAC pathogenesis. We established a new 
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glycoprotein biomarker pipeline which couples lectin-based glycoprotein isolation with state-of-
the-art discovery and targeted proteomics (20-22). We then applied it to identify and verify 
changes in lectin binding profile of serum glycoproteins between healthy, BE and EAC patients 
(22). Here, we report results from validation in independent cohorts, and evaluation of biomarker 
panels for surveillance of BE patients.  
EXPERIMENTAL PROCEDURES 
Clinical cohorts 
Ethical approval was obtained from all participating institutions, and all patients provided 
informed consent to participate in the studies. We investigated two independent cohorts recruited 
in Australia and the United States of America, respectively. The Australian samples were selected 
from participants recruited into The Progression of Barrett's Esophagus to Cancer Network 
(PROBE-NET) study across 4 states (New South Wales, Queensland, South Australia and 
Victoria). A total of 252 serum samples collected from 242 patients were analyzed [Normal – 43, 
BE – 65, BE-LGD – 39, BE-HGD – 35, and EAC – 60, at baseline]. Of the 252 serum samples, 
10 samples were from patients who progressed to the subsequent stage of the disease while 242 
were baseline serum. Independently, a cross-sectional cohort of 49 serum samples collected at 
Ochsner Health System, New Orleans, United States were also analyzed. Nine of the Ochsner 
patients in the Normal group had a history of Barrett’s related pathology and received endoscopic 
treatments. These patients were confirmed to have no Barrett’s mucosa by histology at the time of 
serum collection, however they may have submucosal disease, hence the normal groups will be 
now onwards called non-specialized epithelium [NSE, epithelium without Barrett’s mucosa]. The 
Ochsner cohort comprised of 14 NSE, 13 BE, 3 BE-ID (Barrett’s mucosa which is indefinite for 
dysplasia), 2 BE-LGD, 7 BE-HGD, and 10 EAC patients. 
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Similar procedure of serum collection was followed across all sites. Briefly, 10 mL of 
blood was collected by trained phlebotomists into Vacutainer red top collection tubes [Becton 
Dickinson (BD)]. Once in the lab, the blood was allowed to coagulate at room temperature for a 
minimum of 20 minutes. The tubes were centrifuged at 3000 RPM (Beckman CS-6R) for 10 
minutes at 22°C (brake off) making sure that all blood was separated. Using sterile pipette, the 
serum was removed, aliquots were prepared and stored at -80°C. Serum samples were shipped to 
the Translational Research Institute, Brisbane on dry ice for this study. The clinical diagnosis 
linked to the sample was based on histological examination of biopsies taken at the same 
endoscopy. The diagnoses were provided to the researcher performing the biomarker candidate 
measurements to allow batch randomization design for the assay. Formalin-fixed, paraffin-
embedded (FFPE) tissue sections from the Ochsner Health System were selected and shipped to 
Brisbane, Australia for immunohistochemistry.  
Both PROBE-NET and the Ochsner cohort provided information on patients’ age, sex and 
body mass index (BMI, calculated as weight (kg) / [height (m)]2); whereas ethnicity was provided 
by the Ochsner cohort only and education, alcohol drinking and tobacco smoking was only 
available in the PROBE-NET cohort. Data on demographics and lifestyle factors were compared 
among different clinical and histological groups using Pearson’s chi-square test or Fisher’s exact 
test as appropriate. P < 0.05 was considered to be statistically significant. Analyses were performed 
using SAS 9.4 software. 
Lectin magnetic bead array (LeMBA) and multiple reaction monitoring (MRM)-mass 
spectrometry  
AAL (Aleuria aurantia lectin), EPHA (erythroagglutinin from Phaseolus vulgaris), JAC 
(jacalin from Artocarpus integrifolia), and NPL (Narcissus pseudonarcissus lectin) (Vector 
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Laboratories, Burlingame, CA) were individually conjugated to MyOne tosyl-activated 
Dynabeads® (Life Technologies) as previously described (20). Total serum protein concentration 
was measured using bicinchoninic acid (BCA) assay (Pierce) (23). 50 μg of serum protein samples 
were spiked with chicken ovalbumin as an internal standard and were denatured as described 
previously (22). LeMBA pull-downs were performed using Bravo liquid handler (Agilent 
Technologies). The Bravo protocol and device files are available in supplemental method. The 
pull-down proteins were digested into peptides by on-bead enzymatic treatment with protease 
trypsin at 37°C for overnight (Modified sequencing grade trypsin from Promega, Madison, WI), 
vacuum-dried, and stored at -80 °C. The dried peptide samples were reconstituted in 0.1% formic 
acid, and then a mixture of ten synthetic stable isotope standard (SIS) labelled peptide was spiked-
into the sample. The concentration of each of these ten SIS peptides was optimized so that their 
response fell within ±10-fold of natural peptide. The sequence of SIS labelled peptide along with 
the protein candidate they represent is as follows: VTSIQDWVQK (Haptoglobin or P00738 or 
HP), AVEVLPK (Gelsolin or P06396 or GSN), NLAVSQVVHK (α-1-antichymotrypsin or 
P01011 or SERPINA3), LPPNVVEESAR (α-2-macroglobulin or P01023 or A2M), 
LSPIYNLVPVK (Complement component C9 or P02748 or C9), SPAFTDLHLR (Apolipoprotein 
B-100 or P04114 or APOB), GSFEFPVGDAVSK (Complement C4-B or P0C0L5 or C4B), 
LTPLYELVK (Complement component C7 or P10643 or C7), VASMASEK (Ovalbumin or 
P01012 or SERPINB14), and ISQAVHAAHAEINEAGR (Ovalbumin or P01012 or 
SERPINB14). The SIS peptides ISQAVHAAHAEINEAGR and VASMASEK that represent 
ovalbumin internal standard generated poor quality data and were not considered for data analysis. 
As an inter-batch quality control (QC) for processing of the PROBE-NET cohort, serum sample 
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from a healthy volunteer was used in 4 wells of each 96-well plate. This was not required for the 
Ochsner cohort due to the smaller sample size per lectin. 
The MRM-MS assay was set up on Agilent Technologies 6490 triple quadrupole mass 
spectrometer coupled with 1290 standard-flow infinity Ultra-High Performance Liquid 
Chromatography (UHPLC) fitted with a standard-flow ESI (Jet Stream) source. Agilent 6490 triple 
quadrupole mass spectrometer was operated in positive ion mode using Agilent’s MassHunter 
Work station software (version B.06.00). The MRM acquisition parameters were 150 V high 
pressure RF, 60 V low pressure RF, 4000 V capillary voltage, 300 V nozzle voltage, 11 L/min 
sheath gas flow at a temperature of 250 °C, 15 L/min drying gas flow at a temperature of 150 °C, 
30 psi nebulizer gas flow, unit resolution (0.7 Da full width at half maximum in the first quadrupole 
(Q1) and the third quadrupole (Q3)), and 200 V delta EMV (+). A blank was injected after every 
sample during LC-MS/MS data acquisition. Periodically, human serum albumin synthetic peptide 
standard mix (#G2455-85001, Agilent Technologies) was injected as quality control to monitor 
the mass spectrometer performance over a long period of time.  
The precursor ions and transitions were selected based on discovery experiments described 
earlier (22) and through in silico analysis using Skyline (24). The list of transitions containing 
precursor m/z, product m/z, collision energy, retention time, and delta retention time for PROBE-
NET and Ochsner cohorts are reported in Supplemental Table 1. The UHPLC system consisted of 
a reverse phase AdvanceBio Peptide Mapping column (150 × 2.1 mm i.d., 2.7 μm, #653750–902, 
Agilent Technologies) with a 5 mm long guard column. Mobile phase A was 0.1% formic acid, 
and mobile phase B was 100% acetonitrile containing 0.1% formic acid. The UHPLC system was 
operated at a flow rate of 0.4 mL/min at 60 °C. The gradient used for peptide separation was as 
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follows: 3% B at 0 min; 35% B at 40 min; 95% B at 40.5 min; 95% B at 44.5 min; 3% B at 45 
min; followed by conditioning of column for 4 min at 3% B.  
Skyline (version 3.6.0.10493) was used for inspecting and processing MRM data (24). Poor 
quality peptides that showed non-reproducible results [% coefficient of variation (% CV) < 30%] 
for repeatedly processed QC serum sample were removed. Peak picking algorithm in Skyline was 
optimized for improved peak integration. Peak area for each peptide (sum of all transitions) was 
exported. The quality of acquired datasets (Supplemental Table 2A for PROBE-NET cohort and 
Supplemental Table 2B for Ochsner cohort) were evaluated by % CV of spiked-in stable isotope-
labeled internal standard (SIS) peptides and peptides derived from the spiked-in internal standard 
protein chicken ovalbumin. The data were normalized using the median intensity of 8 SIS peptides. 
Peptide intensities were converted into protein intensity with Pearson correlation coefficient cut-
off set at 0.6 (22). As recently highlighted by others (25), this step serves as quality control for 
peptide level measurements resulting in a robust protein level quantitative dataset for down-stream 
statistical analysis. The normalized protein intensities were transformed using the natural 
logarithm and z-scores were calculated to ensure that there were no scale differences between the 
two datasets prior to downstream statistical analysis. 
Statistical analysis 
JMP Pro 13.2 (SAS Institute, Inc., Cary, NC, USA) was used for univariate and 
multivariate biomarker statistical analyses. Univariate logistic regressions were conducted on EAC 
vs NSE outcome, EAC vs BE outcome, and the surveillance outcome (BE-HGD or EAC vs BE or 
BE-ID or BE-LGD), against each of the glycoprotein_lectin biomarker candidates. Odds ratios 
(ORs) with 95% Wald confidence intervals (95% CIs), area under receiver operating characteristic 
curves (AUROCs) and Likelihood Ratio P values were calculated for both PROBE-NET and 
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Ochsner cohorts. Recursive partitioning (also known as Classification and Regression Trees, 
CART) was used to identify a multivariate panel of markers that would discriminate between 
surveillance outcomes (BE-HGD+EAC vs BE+BE-ID+BE-LGD). The PROBE-NET dataset was 
used as the training set to develop predictive models, and the Ochsner dataset was used as the 
validation set. The set of 217 markers that were available in both PROBE-NET and Ochsner 
datasets was used in the training set, as well as baseline characteristics, including age, gender, and 
BMI. To avoid overfitting, models were limited to 6, 8, and 10 biomarker candidates. We also 
implemented a permutation test to assess the performance of the model fitting approach in the 
training set. Specifically, we fit our model to the training set using 5-fold cross-validation and 
noted the AUROC. Then we randomly permuted the response variable (EAC status) and refit a 
new model in exactly the same way and recorded the permutated AUROC. We repeated this 
procedure for 10,000 permutations to build a distribution of AUROCs against which we evaluated 
our observed AUROC. Thus models that tend to overfit the data lead to large AUROCs in the 
permutations relative to the observed AUROC thus allowing us to tune our models to avoid 
overfitting. The prediction formulas derived from PROBE-NET were then applied to the Ochsner 
dataset to determine sensitivity and specificity in the validation set.  
Expression and purification of recombinant C9 
Recombinant C9 protein was produced by transient expression in HEK 293 Expi cells for 
four days. HEK cells were split to a density of 1.2 - 1.5 x 10^6 cells/mL the day prior to 
transfection. Transfections mixtures were setup with a 1:4 ratio (w/w) of huC9-pSectag2a:PEI 
diluted in PBS to 1/10 of the volume of HEK cells containing 1 μg human IgK-C9 DNA/mL of 
cells. The native C9 signal peptide was replaced by an IgK secretion sequence for effective 
secretion into expression media. Following four days expression, the supernatant was obtained by 
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centrifugation at 2000 x rcf and the conductivity of the media was adjusted with 10 mM Na 
phosphate pH 7.4, 20 mM NaCl for binding to a hiTrap DEAE sepharose column. All 
chromatography steps were eluted on ÄKTA FPLC. Protein was eluted on a linear gradient from 
(10 mM Na phosphate pH 7.4, 45 mM NaCl; to 10 mM Na phosphate pH 7.4, 500 mM NaCl) over 
20 column volumes. Fractions containing C9 were pooled for type I CHT chromatography using 
a 5 mL Bio-Rad pre-packed column and bound at 10 mM Na Phosphate pH 7.0, 100 mM NaCl. 
CHT column was eluted with a phosphate gradient (constant pH 8.1) from 45 - 350 mM over 6 
column volumes. The C9 containing fractions from CHT were concentrated using a 30 kDa 
MWCO concentrator (Amicon) and polished by size exclusion on a superdex 200 16/60 eluted in 
10 mM HEPES pH 7.2, 200 mM NaCl. Following purification, recombinant C9 was concentrated 
to 1.0 mg/mL and aliquots were frozen in liquid nitrogen. 
Immunohistochemical analysis 
Immunohistochemical staining was performed on 42 tissue sections collected from 34 
patients using anti-C9 primary antibody (Sigma Aldrich #SAB4503059). Sections were dewaxed 
in xylene, rehydrated in descending concentrations of ethanol to water and endogenous peroxidase 
quenched with 2% H2O2 in Tris-buffer saline for 10 minutes. Antigen retrieval was carried out in 
a Biocare Medical Decloaking Chamber using Dako Target Retrieval Solution pH 9 for 15 minutes 
at 105 °C. To eliminate nonspecific background, sections were treated at room temperature with 
Innovex Fc Receptor Blocker for 30 minutes then Biocare Medical Background Sniper for 15 
minutes. Anti-C9 primary antibody diluted 1:300 in Background Sniper was applied for 60 minute 
at room temperature. To determine antibody specificity, anti-C9 antibody was inactivated by 
incubation with 50 μg/mL C9 recombinant protein for 60 minutes at room temperature before 
application to the slide (Supplemental Figure 1). The slides were then incubated with Universal 
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Polymer HRP for 30 minutes. A Biocare Medical MACH1 HRP kit was used for detection 
according to manufacturer’s recommendations; Betazoid DAB, MACH1 kit, was used to visualize 
antibody signals. Sections were washed in water then haematoxylin counterstained, dehydrated, 
cleared in xylene and coverslipped using a Leica XL automated stainer and CV5030 coverslipper. 
Staining intensities in squamous mucosa, columnar epithelium without intestinal 
metaplasia, Barrett’s esophagus mucosa (with intestinal metaplasia), dysplasia (low and high 
grade), EAC and inflammatory infiltrate were scored by a specialist gastrointestinal pathologist. 
Each component, if present in the tissue, was scored separately using a 4 grade assessment of 
intensity (0 no staining, 1+ weak staining, 2+ moderate staining, 3+ strong staining). Where the 
staining was non-uniform in a component, the maximum intensity of staining was used for the 
score, providing at least 10% of the cells of that component stained to this intensity. Due to limited 
numbers, for statistical analysis, we combined dysplasia with EAC group; similarly, those with 3+ 
staining in Barrett’s mucosa were combined with 2+ staining group. The relationship between 
histological features and the staining intensity was evaluated using Fisher exact test.   
RESULTS 
Workflow of this study is depicted in Figure 1B. We took a sequential approach to discover 
and validate serum diagnostic glycoprotein biomarker candidates. In previous study (22), we 
discovered candidates that differentiate between EAC from NSE and BE groups. In this study, we 
first validate the biomarker candidates for EAC in two independent cohorts. As BE-HGD is 
expected to be an intermediate phenotype progressing towards EAC, next, we evaluated ability of 
the biomarker candidates to aid current surveillance program i.e. distinguish between patients who 
require follow-up endoscopy (BE-HGD and EAC) and those who do not (BE, BE-ID and BE-
LGD).  
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Table 1 details the baseline demographic and clinical characteristics of the Australian 
(PROBE-NET) and Ochsner cohorts. Serum glycoprotein biomarker candidates were measured 
using our previously reported lectin magnetic bead array (20, 21)-coupled multiple reaction 
monitoring (MRM) mass spectrometry assay (26). In this method, lectin binding is used to isolate 
glycoproteins with particular glycan structures. Based on our previous work for BE/EAC (22, 27), 
four lectins were selected for the independent validation cohorts, namely AAL, EPHA, JAC, and 
NPL. The targeted proteomics workflow uses a tier 3 assay with inclusion of internal standard 
peptides for 8 candidates. As compared to previously published MRM-MS assay that analyzed 41 
glycoprotein candidates (22), ~40 more target proteins were added to the assay (Supplemental 
Table 1). The uniqueness of target peptides was established using Skyline with human proteome 
as a background. The assay reproducibility was tested as described earlier (22). PROBE-NET and 
Ochsner cohorts were independently analyzed with block randomization design for each cohort.  
Univariate analysis of the PROBE-NET cohort dataset revealed 46 and 54 biomarker 
candidates with P<0.05 for EAC vs NSE and EAC vs BE comparisons respectively (Supplemental 
Table 3). Data for the top 10 biomarker candidates that differentiate EAC from NSE, and EAC 
from BE in PROBE-NET cohort are shown in Figure 2A and 2B, respectively. Out of these 
candidates, 16 candidates for EAC vs NSE comparison and 9 candidates for EAC vs BE 
comparison were also significantly different in the Ochsner cohort, confirming these glycoproteins 
as validated biomarker candidates. As illustrated in Figure 2C, 8 validated biomarker candidates 
overlap between the two lists. These biomarker candidates are potentially most useful, being able 
to distinguish EAC from NSE and BE. The 8 biomarker candidates comprised of 4 glycoproteins, 
namely, complement C9 (C9), gelsolin (GSN), serum paraoxonase/arylesterase 1 (PON1), and 
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serum paraoxonase/lactonase 3 (PON3), that were different between the disease groups in one or 
more lectin pull-down samples.  
 Next we considered BMI as a potential confounding factor for EAC biomarker validation. 
Correlation analysis between BMI and biomarker candidate levels in all PROBE-NET samples 
revealed no substantial correlation (|r|<0.6) (Supplemental Table 4), although three proteins 
namely complement C3 (C3), C4b-binding protein alpha chain (C4BPA), and complement factor 
I (CFI) with multiple lectin pull-downs showed positive correlations with BMI in NSE patients 
only (|r| 0.6234-0.7069). Importantly, none of the top 10 biomarker candidates showed strong 
correlation with BMI. This suggests that top glycoprotein biomarker candidates measured using 
our workflow are not affected by a common confounding covariate, BMI.  
Biomarkers for BE surveillance  
Having confirmed univariate biomarkers for detection of EAC from NSE and BE in 
independent cohorts, we next evaluated the ability of serum glycoproteins to be used as a 
surveillance tool for BE and BE-LGD patients, i.e. to distinguish between patients who require 
treatment (BE-HGD and EAC) and those who do not (BE, BE-ID and BE-LGD). Eight biomarker 
candidates that showed AUROC > 0.6 in a BE surveillance setting for both PROBE-NET and 
Ochsner cohort (Figure 3, Supplemental Table 3), comprised of GSN measured in AAL, NPL, and 
JAC pull-downs, C9 measured in JAC and EPHA pull-downs, AAL-binding PON1, AAL-binding 
PON3, as well as EPHA-binding Complement factor B (CFB).  
Next we sought to generate a multimarker panel for BE surveillance, using the PROBE-
NET cohort for modeling and Ochsner cohort for model validation. The minimal panel of six 
biomarker candidates showed 0.83 AUROC, 83% sensitivity and 69% specificity for the PROBE-
NET cohort, and a moderate sensitivity of 61% and specificity of 65% for the Ochsner cohort 
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(Table 2). Addition of 4 more biomarker candidates to the panel increased the AUROC to 0.93, 
and improved the specificity and sensitivity measures for PROBE-NET, as well as the specificity 
for Ochsner cohort (Table 2). Further evaluation of this multimarker panel of 10 biomarker 
candidates in a subset of Ochsner cohort comprising of only treatment naïve patients (N = 20) 
showed sensitivity of 71% and specificity of 77% to distinguish between the two groups. The 
performance of multimarker panel in a subset of treatment naïve Ochsner cohort is similar, if not 
slightly improved, as compared to results obtained using all available Ochsner cohort samples. 
Complement C9 expression in BE and EAC tissue 
In agreement with our previous finding of complement pathway dysregulation in EAC 
pathogenesis (22), 5 of the 10 glycoprotein biomarker candidates in the final surveillance 
biomarker panel (Table 2) belonged to the complement pathway. As a first step to evaluate 
alterations of the complement pathway in EAC at a tissue level, we optimized 
immunohistochemistry staining for the top candidate, complement C9. Staining specificity of the 
method was confirmed by neutralization of the antibody with recombinant C9 protein prior to 
staining. In Supplemental Figure 1, the disappearance of dark brown tissue staining after pre-
incubation of anti-C9 antibody with recombinant C9 indicates the antibody specificity. We then 
evaluated expression of C9 in esophageal tissue sections from a subset of the Ochsner cohort. As 
shown in Figure 4A, the adjacent normal squamous epithelium tissue showed no or minimal C9 
staining as compared to light to dark brown staining that was detected in BE and EAC. Dysplastic 
BE showed particularly strong staining in the plasma membrane and/or cytoplasm (Figure 4A). 
Strong staining in immune infiltrates served as an expected positive control. Quantitation of 
staining intensity score against the tissue phenotype (Figure 4B) showed statistically significant 
association between C9 expression levels and histology groups of squamous epithelium, columnar 
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epithelium, Barrett’s mucosa, dysplasia/EAC (P<0.001). Specifically, 87% of the squamous 
epithelium showed no C9 staining as compared to all of the BE, dysplastic, or EAC tissue that 
showed some degree of C9 presence. In addition, 87% of BE and 67% dysplastic/EAC 
observations were positive for C9 with scoring intensity ≥2. In contrast, none of the squamous 
epithelia were stained strongly (intensity ≥2) for C9. Columnar epithelium with no evidence of 
intestinal metaplasia showed intermediate C9 staining. These novel data demonstrating elevated 
C9 protein in Barrett’s and EAC cells provides some biological basis, to the use of elevated serum 
C9 as a biomarker candidate. The exact correlation between tissue and serum C9 remains to be 
established.  
Serum complement C9 in progressor samples 
As an additional evaluation, we examined C9 lectin pull-down levels in samples from 
PROBE-NET participants who had progressed from BE to BE-LGD (N = 4), BE-LGD to BE-
HGD (N = 3), BE to BE-HGD (N = 1), BE to EAC (N = 1), and NSE to gastric type mucosa (N = 
1) phenotype during follow-up. The progression time varied from 110 days up to 5 years. 
Significant elevation of C9_EPHA and C9_NPL was observed following progression in this small 
patient cohort (Figure 5). 
DISCUSSION 
This study progresses our previous serum glycoprotein research (22, 27) towards 
developing cost-effective EAC surveillance by validating serum biomarker candidates in two 
independent cohorts. Over the years, several studies have been carried out to identify circulatory 
biomarker candidates to diagnose BE-dysplasia-EAC disease spectrum (19, 28). These studies 
have explored genetic alterations in cell free circulating DNA (29), serum miRNA changes (30), 
circulating tumor cells (31), glycan profile alteration in serum (32, 33), circulatory autoantibodies 
19 
 
(against cancer antigens) (34), volatile organic compounds found in breath analysis (35), metabolic 
changes in urine (36), and a panel of serum proteins (37) as promising diagnostic biomarker 
candidates for BE and/or EAC. However, none of these biomarker candidates have progressed 
from bench to bedside, likely due to the lack of subsequent validation studies in large independent 
cohort of patients. Here, we have addressed this gap by validating eight serum glycoprotein 
biomarkers for EAC in two independent patient cohorts including dysplastic samples. 
In addition to demonstrating the robustness of our mass spectrometry based glycoprotein-
centric proteomics workflow for biomarker validation, the current study confirmed our previous 
finding of complement activation in EAC (22). The complement system consists of a cascade of 
circulating proteases that are locally activated leading to the formation of the membrane attack 
complex on the immunogen and recruitment of phagocytes. Complement components are 
predominantly expressed and secreted into the plasma by the liver but are also found to be 
expressed in other tissues (38), including tumor cells (39). While complement components are 
primarily involved in mediating innate immune response, recent studies have revealed an 
apparently paradoxical tumor-promoting role of the complement system (39, 40). Complement C3 
has been reported to play an autocrine role in ovarian and lung cancer tumor growth (41). C5a is 
elevated in serum of lung cancer patients (42) and increases the invasiveness of C5aR+ tumors 
(43). Recently, Franc and colleagues found 15 co-occurring serum C9 proteoforms based on glycan 
expression profiling (44). Specifically, fucosylated C9 was reported to be elevated in the serum of 
lung cancer patients (45).  
Two previous publications reported on complement component changes in BE and EAC. 
Bobryshev et al. reported reduced C1q expression in dendritic cells and macrophages in the 
epithelium of BE and EAC, and suggest this to be an immune-escape mechanism (46). Song et al. 
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identified complement pathway proteins, complement C3 and complement C1r subcomponent to 
be increased in serum collected from BE-HGD and EAC patients respectively as compared to 
disease free individuals (47). The current study is the first to report C9 protein expression in BE 
and EAC cells, as demonstrated on tissue sections. In addition to validating our previous finding 
of elevated circulating C9 in LeMBA pull-downs in EAC, we also evaluated the utility of serum 
C9_JAC and C9_EPHA for BE surveillance in independent cohorts. Together, our results suggest 
a pathological change in the secretion, glycosylation, or expression of C9 during the progression 
of BE to BE-HGD/EAC. Modulation of C9 expression is unlikely to be the mechanism, since we 
detected strong C9 staining in both BE and BE-HGD tissue. Interestingly, bile (deoxycholic acid) 
treatment was reported to alter glycosylation and Golgi structure in esophageal epithelial and BE 
cells, resulting in impaired protein secretion via the classical pathway (48). Hence, C9 may be 
sequentially regulated by expression level and glycosylation/secretion during BE-EAC 
progression. Further studies are required to determine the precise molecular changes in serum C9 
with respect to normal-BE-dysplasia-EAC spectrum.  
The strengths of this study include the validation of biomarker candidates in independent 
cohorts, evaluation of biomarker panel for BE surveillance, and the use of immunohistochemistry 
to determine the cellular origin of the top serum glycoprotein biomarker candidate. There are 
several limitations to our study. While our glycoprotein biomarker pipeline allows high-throughput 
glycoprotein biomarker discovery and validation, changes in the glycosylation site occupancy or 
glycan structural changes for the biomarker candidate are not determined. Furthermore, the 
functional consequences, if any, of these glycosylation changes in cancer progression also remain 
to be evaluated. The tier 3 mass spectrometry assay employed in our work may suit early stage 
validation studies but the final biomarker panel should be evaluated with tier 1 MRM-MS assay 
21 
 
(or similar other assay platform) that allows absolute quantification. The small number of 
progressor samples available is a limitation, not only for the current study, but for evaluation of 
BE/EAC biomarkers in general. International collaborations and longitudinal cohort sampling are 
therefore required to advance the search for EAC biomarkers. Finally, the tissue expression of C9 
and other candidates also need to be confirmed in a larger number of samples. 
In summary, we have validated a number of serum glycoprotein biomarkers that warrant 
further clinical testing in large independent cohorts including longitudinal patient samples. Further 
evaluation and development of these biomarkers to a blood test may aid the current endoscopy-
biopsy surveillance program of BE patients for early detection of dysplastic progression.  
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FIGURE LEGENDS 
Figure 1. (A) Pathogenesis of esophageal adenocarcinoma (EAC) and clinical management of 
patients during each stage. In response to exposure to gastric and bile acid, non-specialized  
esophageal epithelium (NSE) converts to Barrett’s esophagus (BE), and may progress through low 
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grade dysplasia (LGD) and high grade dysplasia (HGD) stages to EAC. Patients at high risk of 
BE undergo endoscopic screening to detect asymptomatic metaplastic BE condition. Patients with 
BE or BE-LGD undergo endoscopy-biopsy surveillance to detect BE-HGD for endoscopic 
treatments. (B) Workflow of the study. A total of 301 serum samples from two different patient 
cohorts were subjected to lectin magnetic bead array-coupled multiple reaction monitoring mass 
spectrometry (LeMBA-MRM-MS). Biomarker candidates for EAC and surveillance were 
identified by statistical analysis. Tissue expression of top glycoprotein biomarker candidate 
complement C9 was evaluated by immunohistochemistry. 
Figure 2. Serum glycoprotein biomarker validation in PROBE-NET and Ochsner cohorts. 
Top 10 glycoprotein_lectin biomarker candidates that differentiate (A) esophageal 
adenocarcinoma (EAC) from non-specialized epithelium (NSE) and (B) EAC from Barrett’s 
esophagus (BE) in PROBE-NET and Ochsner cohorts. (C) Overlap of validated biomarker 
candidates (P<0.05). Biomarker candidates are shown by gene name and lectin affinity, and 
ordered by P value. Horizontal bar indicates odds ratio (OR) with 95% Wald confidence intervals. 
Likelihood Ratio P values were calculated to test statistical significance in the univariate logistic 
regressions. Area under receiver operating characteristic curve (AUROC) indicates diagnostic 
ability of individual biomarker candidate. AAL = Aleuria aurantia lectin; C9 = complement C9; 
EPHA = erythroagglutinin Phaseolus vulgaris; GSN = gelsolin; JAC = jacalin from Artocarpus 
integrifolia; KLKB1 = plasma kallikrein; NPL = Narcissus pseudonarcissus lectin; PON1 = serum 
paraoxonase/arylesterase 1; PON3 = serum paraoxonase/lactonase 3; SERPINA1 = alpha-1-
antitrypsin.  
Figure 3. Serum glycoprotein biomarker candidates for BE surveillance in PROBE-NET and 
Ochsner cohorts. Candidates that distinguish patients who require confirmatory endoscopy (BE-
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HGD+EAC) from those who do not (BE+BE-ID+BE-LGD) with an area under receiver operating 
characteristic curve (AUROC) value of > 0.6 in both PROBE-NET and Ochsner cohorts are 
shown. Odds ratio (OR) with 95% Wald confidence intervals, likelihood ratio P values and 
AUROC values for (A) PROBE-NET cohort and (B) Ochsner cohort. AAL = Aleuria aurantia 
lectin; AUROC = area under receiver operating characteristic curve; BE = Barrett’s esophagus; 
BE-HGD = BE with high-grade dysplasia; BE-LGD = BE with low-grade dysplasia; C9 = 
complement  C9; CFB =  complement factor B; CI = confidence interval; EAC = esophageal 
adenocarcinoma; EPHA = erythroagglutinin Phaseolus vulgaris; GSN = gelsolin; JAC = jacalin 
from Artocarpus integrifolia; NPL = Narcissus pseudonarcissus lectin; PON1 = serum 
paraoxonase/arylesterase 1; PON3 = serum paraoxonase/lactonase 3. 
Figure 4. Immunohistochemical analysis of complement C9 (C9) in lower esophageal 
biopsies. (A) A panel of representative images of C9 staining in squamous epithelium, Barrett’s 
mucosa, dysplastic epithelium, and esophageal adenocarcinoma conditions. The left image shows 
2+ staining in the non-dysplastic Barrett’s epithelium. The middle image shows 1+ and 3+ staining 
in the BE. The right image shows 2+ staining in cancer cells and 3+ staining in inflammatory cells. 
(B) Summary of C9 staining intensity according to histology groups. P value from Fisher exact 
test. EAC = esophageal adenocarcinoma; IM = intestinal metaplasia.    
Figure 5. Serum complement C9 (C9) levels in specific lectin-pulldowns in PROBE-NET 
progressor serum samples. C9 levels in lectin pull-downs are expressed as ratio of intensity of 
natural peptide LSPIYNLVPVK to stable isotope labeled spiked-in peptide response. The changes 
in C9 in lectin pull-down samples of participants who progressed from one stage (baseline) to 
another stage of the disease at follow-up. P value from paired t-test. AAL = Aleuria aurantia lectin; 
BE = Barrett’s esophagus; BE-HGD = BE with high-grade dysplasia; BE-LGD = BE with low-
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grade dysplasia; C9 = complement C9; EAC = esophageal adenocarcinoma; EPHA = 
erythroagglutinin Phaseolus vulgaris; JAC = jacalin from Artocarpus integrifolia; NPL = 
Narcissus pseudonarcissus lectin; SIS = stable isotope standard. 
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Table 1. Baseline demographics, histologic and clinical characteristics of the study cohorts (N = 
291). 
Characteristics All1 Histology diagnosis P2 
 N (%) 
NSE 
N (%) 
BE 
N (%) 
BE-LGD 
N (%) 
BE-HGD 
N (%) 
EAC 
N (%)  
Ochsner Cohort (N) 49 14 13 5 7 10  
Age at baseline       <0.001 
    <60 11 (22) 4 (29) 3 (23) 2 (40) 1 (14) 1 (10)  
    60-69 22 (45) 5 (36) 4 (31) 3 (60) 3 (43) 7 (70)  
    ≥70 16 (33) 5 (36) 6 (46) 0 3 (43) 2 (20)  
Sex       0.83 
    Female 11 (22) 3 (21) 2 (15) 2 (40) 2 (29) 2 (20)  
    Male 38 (78) 11 (79) 11 (85) 3 (60) 5 (71) 8 (80)  
Ethnicity       0.57 
    Caucasian 45 (92) 12 (86) 12 (92) 5 (100) 6 (86) 10 (100)  
    Hispanic/Latino 1 (2) 0 1 (8) 0 0 0  
    African-American 3 (6) 2 (14) 0 0 1 (14) 0  
BMI at baseline       0.19 
    <25 12 (24) 2 (14) 7 (54) 0 1 (14) 2 (20)  
    25-29.9 15 (31) 3 (21) 2 (15) 2 (40) 3 (43) 5 (50)  
    ≥30 22 (45) 9 (64) 4 (31) 3 (60) 3 (43) 3 (30)  
PROBENET (N) 242 43 65 39 35 60  
Age at baseline       0.04 
    <60 95 (39) 24 (57) 29 (45) 11 (28) 11 (31) 20 (33)  
    60-69 74 (31) 14 (33) 16 (25) 17 (43) 11 (31) 16 (27)  
    ≥70 73 (30) 5 (10) 20 (31) 11 (30) 13 (37) 24 (40)  
Sex       <0.001 
    Female 58 (24) 28 (64) 10 (15) 7 (18) 4 (11) 9 (15)  
    Male 184 (76) 15 (36) 55 (85) 32 (82) 31 (89) 51 (85)  
Education       0.57 
    High School 87 (40) 13 (32) 25 (40) 17 (49) 11 (37) 21 (40)  
    College equivalent  91 (41) 16 (39) 26 (42) 12 (34) 12 (40) 25 (48)  
    University 42 (19) 12 (29) 11 (18) 6 (17) 7 (23) 6 (12)  
BMI at baseline       0.41 
    <25 45 (22) 13 (32) 14 (24) 3 (10) 6 (20) 9 (19)  
    25-29.9 94 (45) 13 (32) 26 (44) 16 (51) 13 (43) 26 (54)  
    ≥30 69 (33) 14 (35) 19 (32) 12 (39) 11 (37) 13 (27)  
Alcohol drinking        0.45 
    Never 32 (14) 9 (22) 8 (13) 5 (14) 2 (6) 8 (15)  
    Ever 190 (86) 32 (78) 54 (87) 30 (86) 30 (94) 44 (85)  
Tobacco smoking        0.18 
    Never 73 (33) 15 (37) 26 (42) 12 (34) 6 (19) 14 (27)  
    Ever 149 (67) 26 (63) 36 (58) 23 (66) 26 (81) 38 (73)  
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1 counts in subcategories may not add up to the total number because of missing data.  
2 χ2 test or Fisher exact test as appropriate. 
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Table 2. Glycoprotein biomarker panel performance for BE surveillance (BE-HGD+EAC vs 
BE+BE-ID+BE-LGD) in PROBE-NET and Ochsner cohorts. 
Multimarker panel 
PROBE-NET cohort Ochsner cohort  
AUROC Sensitivity Specificity Sensitivity Specificity 
Panel 1:  
C9_EPHA + PON1_AAL + 
SERPINA4_EPHA + 
RBP4_AAL + C1QB_JAC + 
PGLYRP2_NPL 
 
0.83 83% 69% 61% 65% 
Panel 2: Panel 1 +  
CP_NPL + C4BPB_JAC + 
C2_EPHA + C4B_AAL 
0.93 86% 85% 61% 71% 
AAL = Aleuria aurantia lectin; AUROC = area under receiver operating characteristic curve; BE 
= Barrett’s esophagus; BE-HGD = BE with high-grade dysplasia; BE-LGD = BE with low-grade 
dysplasia; C1QB = Complement C1q subcomponent subunit B; C2 = Complement C2; C4B = 
Complement C4-B; C4BPB = C4b-binding protein beta chain; C9 = complement component C9; 
CP = Ceruloplasmin; EAC = esophageal adenocarcinoma; EPHA = erythroagglutinin Phaseolus 
vulgaris; GSN = gelsolin; JAC = jacalin from Artocarpus integrifolia; NPL = Narcissus 
pseudonarcissus lectin; PGLYRP2 = N-acetylmuramoyl-L-alanine amidase; PON1 = serum 
paraoxonase/arylesterase 1; PON3 = serum paraoxonase/lactonase 3; RBP4 = Retinol-binding 
protein 4; SERPINA4 = Kallistatin. 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
 
 
 
 
 
 
